Table 1 List of parameters measured in PROMISE-1 and PROMISE-2 where 300-mg was favored over 100-mg dose in predicting ≥ 50% migraine responder ratea
Time Point (Study) | Subgroup (dose favored) |
|---|---|
Weeks 13‒24 (PROMISE-1) | Body mass index ≥ 30.0 kg/m2 (300 mg) |
Weeks 1‒12 (PROMISE-2) | Baseline monthly migraine days < 15 (300 mg) |
Weeks 1‒12 (PROMISE-2) | EQ-5D-5L any problems with mobility (300 mg) |
Weeks 1‒12 (PROMISE-2) | SF-36 social functioning > 45.0 (300 mg) |
Weeks 13‒24 (PROMISE-2) | EQ-5D-5L any problems with mobility (300 mg) |
Weeks 13‒24 (PROMISE-2) | SF-36 vitality > 45.0 (300 mg) |
Weeks 13‒24 (PROMISE-2) | HIT-6 fed up or irritated < very often (300 mg) |